Cargando…

Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with ≥1 line of therapy (LOT) who received their first stem cell transplant (SCT) within 1 year of initial MM diagnosis were estimated using a large US claims database. Disease prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fonseca, Rafael, Hagiwara, May, Panjabi, Sumeet, Yucel, Emre, Buchanan, Jacqueline, Delea, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093246/ https://www.ncbi.nlm.nih.gov/pubmed/33941766 http://dx.doi.org/10.1038/s41408-021-00431-5

Ejemplares similares

Health-Related and Economic Burden Among Family Caregivers of Patients with Acute Myeloid Leukemia or Hematological Malignancies
por: Yucel, Emre, et al.
Publicado: (2021)

Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis
por: Song, Xue, et al.
Publicado: (2019)

The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
por: MacEwan, Joanna P, et al.
Publicado: (2021)

Estimation of minimally important differences and responder definitions for EORTC QLQ‐MY20 scores in multiple myeloma patients
por: Sully, Kate, et al.
Publicado: (2019)

The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
por: Tzogani, Kyriaki, et al.
Publicado: (2017)

European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
por: Tzogani, Kyriaki, et al.
Publicado: (2019)

Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study
por: Biran, Noa, et al.
Publicado: (2020)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting
por: Rifkin, Robert M., et al.
Publicado: (2019)

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)
por: Tsang, Yuen, et al.
Publicado: (2023)

Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer
por: Hagiwara, May, et al.
Publicado: (2013)

Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study
por: George, Marjorie Patricia, et al.
Publicado: (2023)

Current and projected future economic burden of Parkinson’s disease in the U.S.
por: Yang, Wenya, et al.
Publicado: (2020)

Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population
por: Williams, Setareh A., et al.
Publicado: (2020)

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2023)

Odonata: Who They Are and What They Have Done for Us Lately: Classification and Ecosystem Services of Dragonflies
por: May, Michael L.
Publicado: (2019)

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014)

Incremental increases in economic burden parallels cardiometabolic risk factors in the US
por: McQueen, R Brett, et al.
Publicado: (2016)

Economic Burden of Postoperative Neurocognitive Disorders Among US Medicare Patients
por: Boone, M. Dustin, et al.
Publicado: (2020)

Economic burden of hemophilia B in the US: a systematic literature review
por: Li, Nanxin (Nick), et al.
Publicado: (2019)

Economic Burden of Growth Hormone Deficiency in a US Pediatric Population
por: Kaplowitz, Paul B, et al.
Publicado: (2021)

Economic burden of growth hormone deficiency in a US pediatric population
por: Kaplowitz, Paul, et al.
Publicado: (2021)

Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2021)

Economic burden of cholera in the WHO African region
por: Kirigia, Joses M, et al.
Publicado: (2009)

Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK
por: Danese, Mark D, et al.
Publicado: (2016)

Weighted Least Squares Techniques for Improved Received Signal Strength Based Localization
por: Tarrío, Paula, et al.
Publicado: (2011)

Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort
por: Trudo, Frank, et al.
Publicado: (2019)

Assessing the Economic Burden and Health Care Utilizations of U.S. Veteran Patients with Schizophrenia
por: Xie, Lin, et al.
Publicado: (2013)

Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
por: Tsang, Yuen, et al.
Publicado: (2023)

Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension
por: Zhang, Chang, et al.
Publicado: (2023)

The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States
por: Ogbomo, Adesuwa, et al.
Publicado: (2022)

Do policymakers have any plans to reduce the economic burden of cerebral palsy in Iran?
por: Karami Matin, Behzad, et al.
Publicado: (2019)

1017. Haves vs. Have-Nots in Healthcare Communication: Examining the Paradox Where PLHIV Who Need Quality Discussions with their Providers the Most, Access it the Least
por: Rios, Patricia De Los, et al.
Publicado: (2020)

People have shaped most of terrestrial nature for at least 12,000 years
por: Ellis, Erle C., et al.
Publicado: (2021)

Economic burden of diabetes mellitus in the WHO African region
por: Kirigia, Joses M, et al.
Publicado: (2009)

Particulate Matter Exposure and Preterm Birth: Estimates of U.S. Attributable Burden and Economic Costs
por: Trasande, Leonardo, et al.
Publicado: (2016)

PMON64 Economic Burden of Growth Hormone Deficiency in a US Adult Population
por: Smith, Alden, et al.
Publicado: (2022)

Examining the Healthcare and Economic Burden of Gun Violence in a Major US Metropolitan City
por: Silver, Julia H., et al.
Publicado: (2023)

Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions
por: Zhdanava, Maryia, et al.
Publicado: (2020)

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1ha7cqr0jgbf0b25pjg05rk2ns